Johnson & Johnson will soon start testing its COVID-19 vaccine candidate in U.S. adolescents, the company announced Friday. The company plans to begin testing the vaccine in a small number of 16 and 17 year olds as part of an ongoing Phase 2 trial for adults, gradually expanding the trial to children aged 12-17 after reviewing the initial data.

It is currently enrolling adolescents in Spain and the United Kingdom and expects to start enrolling them soon in the U.S., Netherlands and Canada, followed by Brazil and Argentina.

In February, the U.S. Food and Drug Administration authorized emergency use of the vaccine for individuals 18 and older. 

Related News Articles

News
The Food and Drug Administration today revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Headline
The Biden administration today announced $1 billion in American Rescue Plan Act funding for the Centers for Disease Control and Prevention, states and other…
Headline
The Federal Communications Commission will accept applications for COVID-19 Telehealth Program Round 2 funding from April 29 at 12 p.m. ET to May 6 at 12 p.m.…
Headline
Health care providers participating in the Centers for Disease Control and Prevention’s COVID-19 Vaccination Program must administer the vaccines at no cost to…
Perspective
When President Biden signed legislation on Wednesday eliminating the 2% across-the-board cut to all Medicare payments until the end of 2021, it extended needed…
Headline
Drug overdose deaths in the United States rose by an estimated 29% between September 2019 and September 2020 to 90,237, according to preliminary data …